摘要
目的:观察仑伐替尼联合肝动脉化疗栓塞术(TACE)治疗晚期肝癌患者的效果。方法:选取2021年8月至2023年7月该院收治的66例晚期肝癌患者进行前瞻性研究,按照随机数字表法将其分为对照组和研究组各33例。对照组采用TACE治疗,研究组在对照组基础上联合仑伐替尼治疗,两组均治疗3个月。比较两组临床疗效,治疗前后肝功能指标[丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素(TBIL)]水平、血清学指标[白细胞介素-1(IL-1)、血管内皮生长因子(VEGF)、甲胎蛋白(AFP)]水平,以及不良反应发生率。结果:研究组疾病控制率(DCR)为93.94%(31/33),高于对照组的75.76%(25/33),差异有统计学意义(P<0.05);治疗后,研究组ALT、AST、TBIL水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组IL-1、VEGF、AFP水平均低于对照组,差异有统计学意义(P<0.05);两组骨髓抑制、消化道不适、脱发、发热等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:仑伐替尼联合TACE治疗晚期肝癌患者可提高DCR,降低肝功能指标和血清学指标水平,效果优于单纯TACE治疗。
Objective:To observe effects of Lenvatinib combined with transcatheter arterial chemoembolization(TACE)in treatment of patients with advanced liver cancer.Methods:A prospective study was conducted on 66 patients with advanced liver cancer admitted to this hospital from August 2021 to July 2023.According to the random number table method,they were divided into control group and study group,33 cases in each group.The control group was treated with TACE,while the study group was treated with Lenvatinib on the basis of that of the control group.Both groups were treated for 3 months.The clinical efficacy,the liver function indexes[alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL)]levels,the serological indexes[interleukin-1(IL-1),vascular endothelial growth factor(VEGF),alpha-fetoprotein(AFP)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate(DCR)of the study group was 93.94%(31/33),which was higher than 75.76%(25/33)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of ALT,AST and TBIL in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of IL-1,VEGF and AFP in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as bone marrow suppression,gastrointestinal discomfort,alopecia and fever between the two groups(P>0.05).Conclusions:Lenvatinib combined with TACE in the treatment of the patients with advanced liver cancer can improve the DCR and reduce the levels of liver function indexes and serological indexes.Moreover,it is superior to single TACE treatment.
作者
罗赟
谢自勤
LUO Yun;XIE Ziqin(Department of Oncology of Yudu County People’s Hospital,Ganzhou 342300 Jiangxi,China)
出处
《中国民康医学》
2024年第9期50-52,共3页
Medical Journal of Chinese People’s Health
关键词
晚期
肝癌
肝动脉化疗栓塞术
仑伐替尼
肝功能
血清学
疾病控制率
不良反应
Advance
Liver cancer
Transcatheter arterial chemoembolization
Lenvatinib
Liver function
Serology
Disease control rate
Adverse reaction
